BM

Biomerica IncNASDAQ BMRA Stock Report

Last reporting period 31 Aug, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

BMRA Stock Analysis

BM

Uncovered

Biomerica Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-4/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

16.813 B

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company is headquartered in Irvine, California and currently employs 64 full-time employees. The firm's products are used at the point-of-care in home and in physicians' offices and in hospital/clinical laboratories for detection and treatment of medical conditions and diseases. The firm also engages in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company’s diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances and other medical complications. The Company’s medical diagnostic products are sold primarily in two markets: clinical laboratories and point-of-care.

View Section: Eyestock Rating